VKTX FY2025 SEC EDGAR DEF 14A #69 of 168 in industry

Viking Therapeutics, Inc. CEO pay ratio

The CEO earned $21.3M in FY2025 against median worker pay of $438,331 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-01
Industry
Chemicals & Pharmaceuticals
Industry rank
#69/168

Data updated August 2026

Subscribe to Viking Therapeutics, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
49:1
Below Average (Scale: 0–1000:1)
CEO pay
$21.3M
Median worker
$438,331

Answer first

Viking Therapeutics, Inc.'s FY2025 CEO total of $21.3M ranks #155 of 1,423 complete filings; its 49:1 pay ratio ranks #979. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $438,331. Industry placement uses the FY2025 SIC-28 peer cohort (# 69 of 168, 60th percentile - above the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#155
$21.3M of 1,423 FY2025
Ratio rank
#979
49:1 of 1,423
Industry pct
60th
above the industry median pay ratio

How Viking Therapeutics, Inc. ranks nationally

Viking Therapeutics, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$21,269,833 Top 11% higher than 89% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). Below this entry. $10,000,000–$12,500,000: 139 companies (10%). Below this entry. $12,500,000–$15,000,000: 91 companies (6%). Below this entry. $15,000,000–$17,500,000: 88 companies (6%). Below this entry. $17,500,000–$20,000,000: 54 companies (4%). Below this entry. $20,000,000–$22,500,000: 24 companies (2%). This entry sits in this band. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Viking Therapeutics, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($21.3M) against pay ratio (49:1) for Viking Therapeutics, Inc. (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both2820634.87652567.612484500.517316433.422148366.341.6:143.6:145.5:147.4:149.4:1CEO total payPay ratio (CEO : median worker)Viking Therapeutics, Inc., CEO total pay: 21269833 · Pay ratio (CEO : median worker): 49:1Viking Therapeutics, Inc.Lsb Industries, Inc., CEO total pay: 5363883 · Pay ratio (CEO : median worker): 49:1Lsb Industries, Inc.Neurocrine Biosciences Inc, CEO total pay: 13448935 · Pay ratio (CEO : median worker): 49:1Neurocrine Biosciences IncAlnylam Pharmaceuticals, Inc., CEO total pay: 14984640 · Pay ratio (CEO : median worker): 48:1Alnylam Pharmaceuticals, Inc.Vaxcyte, Inc., CEO total pay: 14585904 · Pay ratio (CEO : median worker): 48:1Vaxcyte, Inc.Valhi Inc /de/, CEO total pay: 3699168 · Pay ratio (CEO : median worker): 48:1Valhi Inc /de/
Viking Therapeutics, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Viking Therapeutics, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Viking Therapeutics, Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2024–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
49:1
FY2025
vs prior FY
+16:1
from FY2024 33:1
CEO $ YoY
+49%
$21.3M latest
Filings shown
2
FY2024–2025
Viking Therapeutics, Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2024 $14.3M - $427,777 33:1 -
2025 $21.3M +49% $438,331 49:1 +16:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1607678, FY2024–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
49:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$21.3M
Companies in Industry
168
vs. Industry Median
Above
#69 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Viking Therapeutics, Inc.: MODEST · PEAK pay ratio

Viking Therapeutics, Inc.'s FY2025 CEO total $21.3M ranks #155 of 1,423 complete filings (higher third by dollars). the CEO earned 49× the median employee ($438,331) in FY2025.

Median employee $438,331 (ELITE-MED); MODEST · PEAK stamps put about 49 median-wage years per CEO year.

CEO Total Pay

$21.3M

FY2025 Summary Compensation, well above median

Pay Ratio

49:1

Below typical

Viking Therapeutics, Inc. in the higher-dollar third

Viking Therapeutics, Inc.'s FY2025 CEO total $21.3M ranks #155 of 1,423 complete filings (higher third by dollars). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Viking Therapeutics, Inc.'s $21.3M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #155 and ratio rank #979 split - treat 49:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$21.3M
Median Employee Pay
$438,331
Pay Ratio
49:1
Filing Date
2026-04-01

Company Info

Ticker
VKTX
CIK
1607678
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1607678, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Viking Therapeutics, Inc.'s FY2025 CEO total $21.3M ranks #155 of 1,423 complete filings (higher third by dollars).

Read with Viking Therapeutics, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · PEAK · ELITE-MED.

Baker Hughes Co · PEAK

ABS(ceo_total_comp) peer at $21.3M (Δ $33K heavier vs Viking Therapeutics, Inc.); HIGH · PAR-MED vs this page's MODEST · PEAK · ELITE-MED.
Vertex Pharmaceuticals Inc / Ma · PEAK

ABS(ceo_total_comp) peer at $21.1M (Δ $126K lighter vs Viking Therapeutics, Inc.); MID · ELITE-MED vs this page's MODEST · PEAK · ELITE-MED.
Stryker Corp · PEAK

ABS(ceo_total_comp) peer at $21.4M (Δ $132K heavier vs Viking Therapeutics, Inc.); STEEP · HIGH-MED vs this page's MODEST · PEAK · ELITE-MED.
Targa Resources Corp. · PEAK

ABS(ceo_total_comp) peer at $21.4M (Δ $173K heavier vs Viking Therapeutics, Inc.); MID · ELITE-MED vs this page's MODEST · PEAK · ELITE-MED.
Lsb Industries, Inc. (SIC 28 pole)

Lsb Industries, Inc. stamps MODEST · MID$ nearest in-SIC by ABS(pay_ratio) to Viking Therapeutics, Inc.'s MODEST filing.
National dual ranks · #155/#979

Viking Therapeutics, Inc.'s FY2025 package sits #155 by CEO dollars and #979 by ratio under PEAK · MODEST.
Ratio primer · MODEST

Viking Therapeutics, Inc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Viking Therapeutics, Inc. (CIK 1607678), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.